These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10784645)

  • 1. Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique.
    Hellmann K
    J Clin Oncol; 2000 May; 18(9):2004-6. PubMed ID: 10784645
    [No Abstract]   [Full Text] [Related]  

  • 2. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
    Schuchter LM; Hensley ML; Meropol NJ; Winer EP;
    J Clin Oncol; 2002 Jun; 20(12):2895-903. PubMed ID: 12065567
    [No Abstract]   [Full Text] [Related]  

  • 3. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
    Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
    J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaphylaxis to dexrazoxane (ICRF-187) following three previous uncomplicated infusions.
    Leoni V; Santini D; Vincenzi B; Grilli C; Onori N; Tonini G
    Allergy; 2004 Feb; 59(2):241. PubMed ID: 14763950
    [No Abstract]   [Full Text] [Related]  

  • 6. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
    Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
    J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small prospective study of chordomas treated with radiotherapy and razoxane.
    Rhomberg W; Böhler FK; Novak H; Dertinger S; Breitfellner G
    Strahlenther Onkol; 2003 Apr; 179(4):249-53. PubMed ID: 12707714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence.
    Hellmann K
    J Clin Oncol; 2007 Oct; 25(29):4689-90; author reply 4690-1. PubMed ID: 17925567
    [No Abstract]   [Full Text] [Related]  

  • 9. Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors.
    Hofland KF; Thougaard AV; Dejligbjerg M; Jensen LH; Kristjansen PE; Rengtved P; Sehested M; Jensen PB
    Clin Cancer Res; 2005 Sep; 11(18):6722-9. PubMed ID: 16166453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
    Jones RL
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
    Swain SM
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexrazoxane: a second look. Prevention of anthracycline cardiotoxicity: useful for some patients.
    Prescrire Int; 2008 Oct; 17(97):195. PubMed ID: 19534047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexrazoxane does not affect treatment outcome in non-Hodgkin's lymphoma patients.
    Rabinovich A; Weiss D; Weissman M; Novack V; Levi I
    Am J Hematol; 2012 Aug; 87(8):830-2. PubMed ID: 22648436
    [No Abstract]   [Full Text] [Related]  

  • 14. Current variations in childhood cancer supportive care in the Netherlands.
    Loeffen EA; Mulder RL; van de Wetering MD; Font-Gonzalez A; Abbink FC; Ball LM; Loeffen JL; Michiels EM; Segers H; Kremer LC; Tissing WJ
    Cancer; 2016 Feb; 122(4):642-50. PubMed ID: 26588808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexrazoxane for anthracycline extravasation.
    Langer SW
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1081-8. PubMed ID: 18028016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant phase II studies of pyrazofurin and razoxane in alkylating agent-resistant cases of epithelial ovarian carcinoma.
    Edmonson JH; Decker DG; Malkasian GD; Webb MJ
    Cancer Treat Rep; 1981; 65(11-12):1127-9. PubMed ID: 7296557
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug Interactions in the Treatment of Malignancy in HIV-Infected Patients.
    Welz T; Wyen C; Hensel M
    Oncol Res Treat; 2017; 40(3):120-127. PubMed ID: 28253501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should anthracyclines and dexrazoxane be used for children with cancer?
    van Dalen EC; van den Berg H; Raphaël MF; Caron HN; Kremer LC
    Lancet Oncol; 2011 Jan; 12(1):12-3. PubMed ID: 21195321
    [No Abstract]   [Full Text] [Related]  

  • 19. Strategies for reduction of anthracycline cardiac toxicity.
    Speyer J; Wasserheit C
    Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NIH program encourages early-career researchers: innovative researchers delve into ways to attack cancer, reduce side effects of chemotherapy.
    Printz C
    Cancer; 2015 Feb; 121(4):487-8. PubMed ID: 25651983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.